Dear Friends and Investors:

Please join us for a special Private Investor Reception on Tuesday, May 21 at 5:30 PM EDT featuring MediMergent (the "Company"), a Real-World Data (RWD) and Evidence (RWE) company committed to humanizing healthcare by unifying patient engagement, proprietary digital technologies, and predictive analytics.

ABOUT THE COMPANY

We produce actionable RWE for diverse healthcare stakeholders through the collection, integration, analysis, and interrogation of multiple sources of RWD from the context of the patient. These sources include medical records, pharmacy and insurance data, laboratory and images, genomics, and importantly, information directly from the “Voice of the Patient”, unfiltered by any third party. Our solutions are utilized to manage diverse research designs that revolutionize product development and commercialization, increase value-based care for payers and providers, and generate insights for improved decision-making across the entire healthcare ecosystem.

We turn data into value through the deployment of AI-driven technologies including applications using synthetic virtual humans and biosensors. Advanced analytics applied to the disparate patient-centric data sources produce adjudicated, reliable, and truthful information that is collected across the healthcare product and service delivery life cycle. By putting the patient at the center of the narrative, our interoperability provides holistic 360-degree views capturing a range of human differences, geographies, diseases and treatment modalities.

Founded as an outgrowth of a long-term collaboration with the Food and Drug Administration, the Company is a mature start-up, revenue-generating, and profitable across the last two years. We have emerging customers from pharma, academia, health insurers/plans, and other healthcare service companies. The founders of our Company have developed ground-breaking therapies and technologies that enable healthcare stakeholders to deliver solutions that improve patients’ lives. Although multiple competitors offer segments of our digital solutions, to our knowledge, there are no competitors, at this time, that integrate all of our software, applications, and service components.

Our “secret sauce” is the development and deployment of virtual humans, customized to incorporate the physical characteristics of caregivers with whom they would feel most comfortable based on sex, age, race, and ethnicity. The AI-driven algorithms track facial expressions, perceived attitudes, comprehension, intent, and overall comfort with the interactions and make adjustments accordingly. Distribution of the data to pre-defined caregivers is managed by the patient via secure, HIPAA-compliant operating systems and procedures. MediMergent owns all of the Intellectual Property and the highly valuable data. Revenue is generated via fee-for-service, licensing of our applications, and subscription agreement for access to data.

FUND INFORMATION

The ASK: $3 million

Uses of Funds:

• Develop the platform from script-based to generative AI

• Conduct a pilot to validate technology

• Sign a minimum of 3 licensing agreements to commercialize the platform

• Expand development staff

NOTE: This Presentation/Reception is for Accredited Investors who can invest $250,000 and Investor Representatives only.

Location

Tysons Plaza Conference Center

First Floor (adjacent to American Prime Restaurant)

1420 Spring Hill Road

McLean, VA, 22102

Light fare, wine, and other refreshments will be served. If you would like more information such as the Company's executive summary and/or investment deck, please email Skylar Rallison at srallison@opus8.com.

We will provide a confirmation email and a calendar invitation after you register. Here is the link to register: https://MediMergentMay21.eventbrite.com

Thanks much and all the best,

The Opus8 Team